Abstract
(Am J Obstet Gynecol 2016;214(1):45–56) Progestogens, natural progesterone or the synthetic 17-hydroxyprogesterone caproate (17-OHPC), are the only class of medication to consistently demonstrate significant reductions in the rate of early preterm birth. The synthetic 17-OHPC and natural progesterone have been studied with the use of a prophylactic strategy in women with a history of preterm birth and in women with a multiple gestation. This review addresses the efficacy and safety of progestogen use, given recent experimental observations regarding pharmacodynamics and the evolving understanding of risk-benefit provided from trials and meta-analysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
